Breaking News, Collaborations & Alliances

Amgen, Roche In Immunotherapy Alliance

Will evaluate investigational candidates in cancer patients

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen and Roche are collaborating on a Phase 1b study to evaluate the safety and efficacy of talimogene laherparepvec, Amgen’s investigational oncolytic immunotherapy, in combination with Roche’s investigational anti-PDL1 therapy, atezolizumab (also known as MPDL3280A), in patients with triple-negative breast cancer and colorectal cancer with liver metastases.   Talimogene laherparepvec is an investigational oncolytic immunotherapy designed to selectively replicate in tumors (but n...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters